Inspire Pharmaceuticals wins award for its denufosol tetrasodium program

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it received the North Carolina Health & Life Sciences Award in the category of “Breakthrough Research” for its denufosol tetrasodium program for cystic fibrosis (CF). This award recognizes innovative research that has the potential to solve problems of great importance to science or society. Inspire received the award at the annual Dinner of Champions, which celebrates leaders in the health and life sciences fields, hosted by the Eastern North Carolina chapter of the National Multiple Sclerosis Society.

“We are honored to receive this award for Inspire’s dedicated research and development of denufosol, a novel compound designed specifically for the treatment of CF lung disease. We believe denufosol has the potential to make an important difference in the lives of CF patients as an early intervention treatment that targets the underlying CF defect. Inspire was founded based on ground-breaking research by scientists at the University of North Carolina at Chapel Hill. We have since developed and advanced the denufosol program to its current Phase 3 clinical testing stage,” stated Christy L. Shaffer, Ph.D., President and CEO of Inspire.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema